Role of MDH2 Pathogenic Variant in Pheochromocytoma and Paraganglioma Patients

Genetics in Medicine - United States
doi 10.1038/s41436-018-0068-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

FGF21 Levels in Pheochromocytoma/Functional Paraganglioma

Cancers
Cancer ResearchOncology
2019English

Clinical Characteristics of Transient Cardiomyopathy in Patients With Surgically Resected Pheochromocytoma and Paraganglioma

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Metabolic Implications of Hypoxia and Pseudohypoxia in Pheochromocytoma and Paraganglioma

Cell and Tissue Research
Forensic MedicinePathologyHistologyCell Biology
2018English

Metabolic Impact of Pheochromocytoma/Paraganglioma: Targeted Metabolomics in Patients Before and After Tumor Removal

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2019English

Efficacy and Safety of Ablative Therapy in the Treatment of Patients With Metastatic Pheochromocytoma and Paraganglioma

Cancers
Cancer ResearchOncology
2019English

Molecular Characterization of Novel Germline Deletions Affecting SDHD and SDHC in Pheochromocytoma and Paraganglioma Patients

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2009English

15 YEARS OF PARAGANGLIOMA: Genetics and Mechanism of Pheochromocytoma–paraganglioma Syndromes Characterized by germlineSDHBandSDHDmutations

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2015English

Precision Medicine in Pheochromocytoma and Paraganglioma: Current and Future Concepts

Journal of Internal Medicine
Internal Medicine
2016English

Therapies Targeting the Signal Pathways of Pheochromocytoma and Paraganglioma

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy